Pfizer says that it is "reviewing strategic alternatives" for its Capsugel business and that divestiture is an option. Capsugel manufactures capsules, including Vcaps hypromellose capsules for inhalation applications, and the Xcelodose powder dispensing system. 2009 revenue for Capsugel was approximately $740 million. Pfizer expects to make a decision early in 2011. Read the company’s press release.
